{"id":40422,"date":"2024-10-15T14:47:34","date_gmt":"2024-10-15T13:47:34","guid":{"rendered":"https:\/\/www.intelligentcio.com\/apac\/?p=40422"},"modified":"2026-07-22T17:15:51","modified_gmt":"2026-07-22T16:15:51","slug":"prenetics-announces-tencents-us30m-million-investment-in-insighta","status":"publish","type":"post","link":"https:\/\/www.intelligentcio.com\/apac\/2024\/10\/15\/prenetics-announces-tencents-us30m-million-investment-in-insighta\/","title":{"rendered":"Prenetics announces Tencent&#8217;s US$30m million investment in Insighta"},"content":{"rendered":"\n<p>Prenetics has announced that&nbsp;Tencent&nbsp;has made a strategic&nbsp;US$30 million&nbsp;investment in Insighta &#8211; a&nbsp;Hong Kong-based early cancer detection company.<\/p>\n\n\n\n<p>This investment values Insighta at&nbsp;US$200 million&nbsp;and underscores Tencent&#8217;s endeavor to advancing AI-powered innovations in healthcare.<\/p>\n\n\n\n<p>Insighta&#8217;s early cancer detection platform is powered by its proprietary FRAGMA technology, a cutting-edge system designed to detect DNA methylation aberrations in cell-free DNA (cfDNA) in bodily fluids such as blood.<\/p>\n\n\n\n<p>Insighta has commenced clinical trials in mainland China, focusing initially on liver cancer, and will soon expand to include lung cancer detection. Insighta is also actively developing tests for additional cancer types, and plans on updating as appropriate.<\/p>\n\n\n\n<p>With&nbsp;US$80 million&nbsp;in cash reserves, Insighta is well-capitalized to fund these trials and expedite the commercialization of its revolutionary cancer detection technology in the next few years.<\/p>\n\n\n\n<p>&#8220;We are excited to welcome&nbsp;Tencent&nbsp;as a strategic investor,&#8221; said Professor&nbsp;Allen Chan, Co-founder, Insighta. &#8220;Their expertise in AI, combined with our proprietary FRAGMA technology, positions us to make significant strides in improving early cancer diagnosis, which can greatly enhance patient outcomes worldwide.&#8221;<\/p>\n\n\n\n<p>&#8220;Tencent&nbsp;sees tremendous potential in Insighta&#8217;s FRAGMA-powered approach to early cancer detection,&#8221; said&nbsp;Alexander Ng, President of&nbsp;Tencent&nbsp;Healthcare. &#8220;We look forward to deepening our partnership with Insighta through various dimensions.\u201d<\/p>\n\n\n\n<p>Danny Yeung, CEO, Prenetics, said: &#8220;This investment marks another significant step for Insighta as it continues its mission to transform cancer detection.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Prenetics has announced that&nbsp;Tencent&nbsp;has made a strategic&nbsp;US$30 million&nbsp;investment in Insighta &#8211; a&nbsp;Hong Kong-based early cancer detection company. This investment values Insighta at&nbsp;US$200 million&nbsp;and underscores Tencent&#8217;s endeavor to advancing AI-powered innovations in healthcare. Insighta&#8217;s early cancer detection platform is powered by its proprietary FRAGMA technology, a cutting-edge system designed to detect DNA methylation aberrations in cell-free [&hellip;]<\/p>\n","protected":false},"author":58,"featured_media":40423,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7027,1463,15,56,25,31,1281],"tags":[1108,7280,7283,7282,121,7281,7279],"class_list":["post-40422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-intelligent-technologies-ai","category-apac","category-digital-transformation","category-east-asia","category-industry-verticals-healthcare","category-intelligent-technologies","category-tech","tag-ai","tag-cancer-detection","tag-cfdna","tag-fragma-technology","tag-hong-kong","tag-insighta","tag-tencent"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/posts\/40422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/users\/58"}],"replies":[{"embeddable":true,"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/comments?post=40422"}],"version-history":[{"count":2,"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/posts\/40422\/revisions"}],"predecessor-version":[{"id":40637,"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/posts\/40422\/revisions\/40637"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/media\/40423"}],"wp:attachment":[{"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/media?parent=40422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/categories?post=40422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.intelligentcio.com\/apac\/wp-json\/wp\/v2\/tags?post=40422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}